49 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
SNY Sanofi $43.75 $109.14B N/A
Article Searches
Alnylam Gets Second Product Approval Amid Stiff Competition http://www.zacks.com/stock/news/646584/alnylam-gets-second-product-approval-amid-stiff-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-646584 Nov 29, 2019 - Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
Sanofi Is Paying a 172% Premium to Buy Synthorx -- and It Sounds Like a Good Deal for Both https://www.fool.com/investing/2019/12/10/sanofi-is-paying-a-172-premium-to-buy-synthorx-and.aspx?source=iedfolrf0000001 Dec 10, 2019 - Sanofi, with sales falling in its older businesses, boosts its higher-growth immuno-oncology business with the $2.5 billion purchase of Synthorx.
Merck to Buy ArQule for $2.7B to Boost Cancer Portfolio http://www.zacks.com/stock/news/663844/merck-to-buy-arqule-for-%2427b-to-boost-cancer-portfolio?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-663844 Dec 10, 2019 - Merck (MRK) offers to acquire ArQule for a deal value of $2.7 billion. The transaction will add ArQule's lead investigational candidate ARQ 531 to Merck's oncology portfolio.
Sanofi (SNY) Looks Good: Stock Adds 6.2% in Session http://www.zacks.com/stock/news/665353/sanofi-sny-looks-good-stock-adds-62-in-session?cid=CS-ZC-FT-tale_of_the_tape|price_movement-665353 Dec 11, 2019 - Sanofi (SNY) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Top Research Reports for Novartis, AbbVie & Sanofi http://www.zacks.com/research-daily/665423/top-research-reports-for-novartis-abbvie-sanofi?cid=CS-ZC-FT-research_daily-665423 Dec 11, 2019 - Top Research Reports for Novartis, AbbVie & Sanofi
Sanofi Says Its $2.5 Billion Biotech Takeover Is Just the Beginning https://www.fool.com/investing/2019/12/14/sanofi-says-its-25-billion-biotech-takeover-is-jus.aspx?source=iedfolrf0000001 Dec 14, 2019 - Sanofi has the perfect gift for investors: Investment in its most promising businesses with plans to keep growing the dividend.
Amicus Progresses on Pipeline Development Amid Competition http://www.zacks.com/stock/news/700524/amicus-progresses-on-pipeline-development-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-700524 Jan 03, 2020 - Amicus (FOLD) progresses with the development of its pipeline. However, the company faces substantial competition.
Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate http://www.zacks.com/stock/news/715508/lilly-to-buy-dermira-for-%2411b-add-phase-iii-eczema-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-715508 Jan 13, 2020 - Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.
Top Stock Analyst Reports for Merck, Broadcom & Sanofi http://www.zacks.com/research-daily/734833/top-stock-analyst-reports-for-merck-broadcom-sanofi?cid=CS-ZC-FT-research_daily-734833 Jan 27, 2020 - Top Stock Analyst Reports for Merck, Broadcom & Sanofi
SNY vs. NVO: Which Stock Should Value Investors Buy Now? http://www.zacks.com/stock/news/736878/sny-vs-nvo-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-736878 Jan 28, 2020 - SNY vs. NVO: Which Stock Is the Better Value Option?

Pages: 12345

Page 1>